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SYNOPSIS 
 
Study Title 
 
 Lamotrigine, an anti-epileptic agent, has been reported as being effective in 
reducing symptoms of neuropathy associated with various etiologies. Based on 
such data, a multi-center , double-blind , placebo controlled, randomized trial will 
be conducted to evaluate the effect of lamotrigine on pain and other neuropathic 
symptoms due to chemotherapy induced peripheral neuropathy ( CIPN ).  
 
 
Objectives 
 
Primary objective: 
 Improvement of pain due to neuronal damage during chemotherapy using the Numerical 
Rating Scale ( NRS ) of pain. 
 
Secondary objectives: 
 Improvement of other chemotherapy induced neuropathic symptoms using the TNS ( 
Total Neuropathy Score ) , improvement of overall quality of life using the EORTC QLQ-
CIPN20. 
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Design, Outcomes, Interventions and Duration 
 The study will employ a randomized , double-blind, placebo controlled design.  Eligible 
patients will be randomly treated with lamotrigine ( target dose of 300 mg , based on published 
data ) versus an identical appearing placebo. Patients will be started on a placebo or lamotrigine 
at dose of 25 mg at bed time for 2 weeks, then 25 mg twice daily for 2 weeks, then 50 mg twice 
daily for 2 weeks , then 100 mg twice daily for 2 weeks and then the dose will be escalated to 
150 mg twice daily, at which time therapy will continue for 12 weeks. Dose escalation will be 
continued per this schedule to allow each patient to reach his/her tolerated dose. After a total of 
22 weeks of therapy from the time of drug initiation patients will be tapered off this drug / 
placebo  over a 4-week period. If a patient wishes to stop sooner for any reason before 22 weeks 
, he/she will be encouraged to taper the drug over a 4-week period rather than discontinuing 
therapy abruptly. 
 For eligible patients baseline NRS ( primary outcome ) , TNS and QLQ-CIPN20 ( 
secondary outcomes ) scores will be obtained . These primary and secondary outcomes, as well 
as adverse events,  will be  assessed weekly over a 22-week period. 
 At the end of the 22 weeks of therapy symptom severity and adverse events will be 
compared with the baseline in both the lamotrigine and placebo arms respectively. 
 Study duration for each patient will be 26 weeks ( 24 weeks of therapy with lamotrigine 
or placebo and additional 4 weeks of tapering off the drug / placebo ) and for each center 
participating in the study 52 weeks ( 28 weeks for subject enrollment and 24 weeks for every 
patient ). 
 
Sample size and population 
Adult patients with symptomatic CIPN ≥  1 month duration because of neurotoxic chemotherapy 
with taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors or combination of 
them will be eligible. To be eligible , patients have to report having 'average' daily pain severe 
enough to have either 1) a rating of ≥ 4 in the NRS or 2) > 1 in the TNS . Serum creatinine ≤ 1,5 
times the upper limit of normal and an estimated life expectancy of ≥ 6 months will be required. 
Patients will be stratified by type of neurotoxic chemotherapeutic agents (taxanes vs platinum 
compounds vs vinca alkaloids vs  proteasome inhibitors vs combination of 2 or more of the 
previous agents ) , age and whether the patient is enrolled during chemotherapy vs after 
completion of therapy. 
The study will have 60 patients in each arm ( a total of 120 patients ) in order to provide 80% 
power. 
The study's flowchart is depicted in the following diagram: 
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Picture 1. Study design 
 
 
 
1. STUDY OBJECTIVES 
1.1 Primary objective 
  The study's primary objective is to evaluate the efficacy of oral lamotrigine twice 
daily up to a maximum dose of 300 mg for 24 weeks in  reducing the 'average' daily NRS pain 
score in patients suffering from CIPN. 
1.2 Secondary objectives 
  The study's secondary objectives are the decline of the TNS score and the 
improvement of the patients' overall quality of life according to the QLQ-CIPN20 at the end of a 
24-week period of therapy with oral lamotrigine . 
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2. BACKGROUND 
 
2.1 Rationale 
 Adult patients with symptomatic CIPN ≥  1 month duration, because of                   
neurotoxic chemotherapy (ie, taxanes [paclitaxel and docetaxel] , platinum compounds 
[carboplatin, cisplatin, and oxaliplatin],vinca alkaloids [vincristine and vinblastine] and 
proteasome inhibitors ( bortezomid )will be eligible.Patients who will be currently receiving 
chemotherapy, as well as those who will have completed therapy at the time of study entry, will 
be eligible. To be eligible, patients have to report having ‘average’ daily pain severe enough to 
have either 1) a rating of  4 using the Numerical Rating Scale ( NRS: 0 = no pain and 10 = worst 
pain possible), or 2) >1 using the TNS score. Serum creatinine 1.5 times the upper limit of 
normal and an estimated life expectancy of  6 months will be required. Patients will be  
ineligible if they have preexisting symptomatic neuropathy because of other causes (eg, 
radiation or malignant plexopathy, lumbar or cervical radiculopathy, vitamin B12 deficiency or 
diabetes), or if they are pregnant or lactating. Patients using the following agents at baseline will 
be ineligible: antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, 
clonazepam, or mexelitine), topical analgesics, and amifostine (although therapy with any of 
these agents can be initiated after study entry, if necessary). The use of NSAIDs will be 
permitted. Lamotrigine is an antiepileptic agent that is reported to inhibit the function of 
neuronal sodium channels in a concentration-dependent and voltage-dependent manner, 
decreasing the release of excitatory neurotransmitters, especially glutamate and aspartate. 
Lamotrigine has been suggested as potentially useful agent for treating pain in neuropathic 
syndromes,based on the observation that increased activity of sodium channels appears to be the  
basis for hyperalgesia (eg, as suggested by the benefit of sodium channel inhibitors such as 
lidocaine on raising the pain threshold).                                
  In normal  volunteers lamotrigine has been demonstrated to raise the threshold to cold-
induced pain compared with placebo.At the time this study is designed,data are available to 
suggest a role for lamotrigine in the therapy of pain from a variety of etiologies, including 
painful diabetic neuropathy, central poststroke pain, human immunodeficiency virus (HIV)-
associated neuropathy and trigeminal neuralgia.  In addition to these data, local anecdotal 
experience of using lamotrigine to treat patients with CIPN suggested that some patients 
appeared to benefit with such therapy, with a reduction in pain and other symptoms (such as 
numbness and tingling). Based on these preliminary data, a phase 3 randomized placebo-
controlled study can be conducted to evaluate the efficacy of lamotrigine in treating pain and 
other neuropathic symptoms resulting from chemotherapy exposure. 
Currently available therapy options for CIPN (eg, opioids or nonsteroidal antiinflammatory 
drugs [NSAIDs]) are suboptimal because they are only minimally effective in relieving 
symptoms (pain and discomfort) of CIPN and/or result in significant adverse events.Tricyclic 
antidepressants and antiepileptics (eg, gabapentin) are often utilized in clinical practice to treat 
CIPN; however, clinical trials evaluating the benefits of such therapies for  therapy or  
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7 
prophylaxis of CIPN do not support such use. Beside bone marrow suppression and renal  
toxicity the neurotoxic side-effects of the most common chemotherapeutic agents are very often 
the reason for stopping the anti-tumour therapy or changing the dose regimen, leading to 
compromised treatment and therefore reduction of the survival rate. 
 
 
2.2    Supporting Data 
 
 CIPN 
 Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of 
several chemotherapeutics used in the treatment of all the most common malignancies. There are 
several defined mechanisms of nerve damage that take place along different areas of the 
peripheral and the central nervous system.[1] It is the most common neurologic complication of 
cancer treatment, particularly with the use of platinum-derived agents, taxanes, vinca alkaloids 
and proteasome inhibitors which are first-line agents in the treatment of solid tumors[2]. 
Chemotherapy regimens that utilize combination therapy may potentiate the sequela of 
neuropathy through agents that produce nerve damage via different mechanisms of action. Initial 
presentation begins with decreased vibration sense in the toes and loss of the ankle jerk reflex. 
Further, neuropathy may present as sensory deficits, loss of motor function and pain due to 
damage that occurs at multiple locations along the peripheral and central nervous system.It is 
estimated that up to 90% ( 60-90 %) of all cancer patients treated with chemotherapy will be 
affected by chemotherapy-induced peripheral neuropathy[3], [4] By example, the development 
of neuropathy is the most common reason for altering a platinum-based chemotherapy regimen, 
either by decreasing dose and frequency or by selecting a different therapeutic agent[5]. 
Depending on the chemotherapy regimen, chemotherapy-induced painful peripheral neuropathy 
may self-resolve in weeks or persist for years[6-8].Studies on the pathophysiology of 
chemotherapy induced peripheral neuropathy suggest anatomical and/or functional changes of 
intraepidermal nerve fibers, primary sensory neurons, CNS neurons,and involvement of glial 
and immune cells.   
 Commonly used CIPN-inducing chemotherapy agents are shown in the following table: 
 
Table 1. Commonly used CIPN-inducing chemotherapy agents [10] 
Classification Agent Type of nerve damage 
Platinum-based compounds Cisplatin 
Carboplatin 
Oxaliplatin 
Sensory 
Vinca alkaloids Vincristine  
Vindesine 
Vinblastine 
Vinorelbine 
Sensory and Motor 
Taxanes Paclitaxel  
Docetaxel 
Sensory and Motor 
Proteasome inhibitors Bortezomid Sensory 
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 Basic science research has demonstrated chemotherapy-induced nerve damage both at the 
level of the peripheral and the central nervous system.Penetration of chemotherapeutic agents 
into the central nervous system is relatively poor, whereas high levels have been found to 
accumulate within the dorsal root ganglia (DRG) and peripheral nerves[11]. 
Activation of innate immunity in the DRG as a consequence of chemotherapy treatment appears 
to be a key early event in the initiation of CIPN[1],[12],[13].The DRG of peripheral nerves are 
susceptible to disruption at many points, including sodium, calcium, and potassium ion 
channels,glutamate-activated N-methyl-D-aspartate (NMDA) receptors, and mitochondria.The 
expression of numerous ion channels in DRG neurons are altered following chemotherapy 
treatment[14]. Activation of ion channels triggers changes in intracellular calcium that leads to 
the release of free radicals that subsequently induce neuropathic pain.Mitochondrial damage also 
increases permeability to and release of intracellular calcium, which causes activation of protein 
kinase C,phosphorylation of transient receptor potential vanilloid (TRPV), activation of capases 
and calpains, and the release of nitric oxide and free radicals.The end result is cytotoxic to axons 
and neuronal cell bodies[15].The alpha-2-delta-1 subunits of calcium channels of the DRG and 
dorsal horn are upregulated by paclitaxel and vincristine. Increased cytosolic calcium is present 
due to the release from extracellular and intracellular stores of mitochondria[16-18]. Paclitaxel, 
vincristine and oxaliplatin increase the Na+ current in the DRG which accounts for the 
paresthesias and fasciculations associated with neuropathy[19-21].There is decreased expression 
of mechano-gated and temperature-sensitive potassium channels (TREK 1, TRAAK types) in 
the presence of oxaliplatin and increased expression of pro-excitatory channels such as the 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels[22]. 
At the mitochondrial level, paclitaxel, vincristine, cisplatin, and bortezomib cause swelling  
and vasculization within the peripheral nerve axon, which increases permeability to and leakage 
of intracellular calcium. This in turn activates a caspase-mediated apoptotic pathway, 
leading to neuronal cell death[23-25]. By increasing cytosolic calcium,oxaliplatin, paclitaxel, 
vincristine, and bortezomib also increase free radicals in DRG cells[26-28].  
 Neuronal apoptosis is also initiated by the activation of calcium-dependent proteases, 
calpains and caspases in DRG cells in the presence of paclitaxel, vincristine, and 
oxaliplatin[29,30].  
The transient receptor potential vanilloids (TRPVs) act as transducers of thermal and chemical 
stimuli in pain-sensing neurons. Cisplatin,oxaliplatin, and paclitaxel upregulate TRPV1 and 
transient receptor potential (TRP) ion channels of the subgroups TRPA1 (transient receptor 
potential cation channel, subfamily A, member 1), TRPM8 (transient receptor potential cation 
channel, subfamily M (menthol), member8 and TRPV4 in the DRG neurons causing nociceptor 
hyperexcitability[31-33]. Substance P and calcitonin gene-related peptide (CGRP) are 
neurotransmitters that relay pain signals and these are increased inDRG neurons by paclitaxel 
and cisplatin[34,35]. Vincristine increases the 5-hydroxytryptamine 2A receptors of 5-
hydroxytryptamine on the DRG neurons and dorsal horn of the spinal cord thereby sensitizing 
spinal dorsal horn neurons and peripheral nociceptive fibers[36,37]. 
The platinum-based chemotherapy agents (oxaliplatin, cisplatin,carboplatin) bind to DNA 
strands thereby inducing apoptotic cell death, particularly within the cell bodies of the DRG. 
Oxaliplatin leads to chronic neuropathy by damaging DNA and by altering the function 
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of voltage-gated sodium channels in the peripheral nerves[38,39]. Of the platinumagents, 
carboplatin is the least likely to produce significant neuropathy. Cisplatin has been found to 
accumulate in the DRG and peripheral nerves[11,40,41].Paclitaxel activates macrophages and 
microglia in the DRG, peripheral nerves and spinal cord. In addition it has been found to 
stabilize microtubules and decrease epidermal nerve fiber density. With large cumulative doses, 
paclitaxel can also affect motor nerves[42,43]. 
 
 Assessment and grading of  CIPN[44,45]: 
 Quantitative assessments of CIPN, such as nerve conduction velocity, vibration 
perception threshold and electromyography, have been applied in the clinical setting. However, 
some of these methods are invasive and uncomfortable for patients, others may lack diagnostic 
value and are costly in terms of time and resources.Of the many existing neuropathic pain 
scales, only a few actually assess the location of the pain, which is an important neurological 
clue. Other important diagnostic clues include the frequency of the pain, whether it is 
spontaneous or induced, the character of the pain in terms of the patient's actual reported 
symptoms and interference with the activities of daily living.   
 The National Cancer Institute Common Toxicity Criteria Evaluation (NCI-CTC) 
evaluation performed by experienced examiners has been shown to overestimate the occurrence 
of motor neuropathy, possibly due to the presence of confounding factors (e.g. fatigue, 
depression, cachexia), which is difficult to exclude without a formal neurological examination.In 
one prospective multi-centre study, 155 patients were treated with Cisplatin/Carboplatin or 
Paclitaxel/Docetaxel, and the neuropathy was examined using the NCI-CTC scale and the Total 
Neuropathy Score (TNS). The TNS was found to be able to detect and estimate the severity and 
the type of CIPN more accurately than the NCI-CTC score, and it has made it possible to 
identify misdiagnosed motor neuropathies. However, some limitations have been recognized. 
For instance, pain is not detected by the scale, although it can represent a severe feature in CIPN 
patients and this evaluation should be added in the clinical work up of these patients. Moreover, 
the presence of sensory or motor impairment in both arms and legs or only in legs does not 
imply a different score, as it depends only on the distal-to-proximal extension of the impairment 
. The full, reduced (TNSr), modified (mTNS) and clinical (TNSc) versions do not adequately 
assess CIPN-related pain severity . Some limited data favour the TNS's psychometric properties 
but further revision and testing of the tool are recommended. 
 Cavaletti et al.  showed the reliability and effectiveness of the simplified TNSc for 
accurately grading and reporting CIPN in comparison with oncological grading scales; 
Although, the work may have been premature, the progress of  TNS is chosen to be the 
secondary objective in the present study, while pain score will be separately measured with the 
NRS score as the primary outcome[44]. 
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 Treatment of CIPN 
 There is no effective CIPN prevention strategy, while treatment of established chronic 
CIPN is limited.Classes of medications utilized include anticonvulsants,antidepressants, opioids, 
non-opioid analgesics, and topicals.Anti-epileptic drugs ( AEDs ) are commonly utilized for 
non-epileptic conditions, including pain syndromes and neuropathic pain. 
 Lamotrigine [46-48] 
Lamotrigine is a novel anti-epileptic agent with at least two anti-nociceptive properties: It 
stabilizes the neural membrane through blocking the activation of voltage-sensitive sodium 
channels , and inhibits the presynaptic release of glutamate. Lamotrigine is absorbed rapidly and 
completely from the gastrointestinal tract. It is approximately 55% bound to plasma proteins. 
The drug is extensively metabolized by conjugation with glucuronic acid. Lamotrigine 
elimination half-time is 25-30 hours.
 
 
 Adverse reactions 
 The drug's adverse reactions are described in the following table: 
 
Table 2 : Lamotrigine's adverse reactions 
 
Body System Frequent  
(≥ 1 %) 
Infrequent 
 (1%-0,1%) 
Rare 
( < 0,1%) 
Body as a whole Ø Allergic reaction, chills, and 
malaise  
Ø 
Cardiovascular  Ø Flushing,hot flashes,  
hypertension, palpitations, 
postural hypotension, syncope, 
tachycardia, and vasodilation 
Ø 
Dermatological Ø Acne, alopecia, hirsutism, 
maculopapular rash, skin 
discoloration, urticaria 
Angioedema, erythema, 
exfoliative dermatitis, 
fungal dermatitis, 
herpes zoster, 
leukoderma,multiforme 
erythema, petechial 
rash, pustular rash,  
Stevens-Johnson 
syndrome,  
vesiculobullous rash 
Digestive Ø Dysphagia, eructation,  
gastritis, gingivitis, increased 
appetite, increased salivation, 
liver function tests abnormal, 
and mouth ulceration 
Gastrointestinal 
hemorrhage, glossitis, 
gum hemorrhage, gum 
hyperplasia, 
hematemesis,  
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hemorrhagic colitis, 
hepatitis,melena,  
stomach ulcer, 
stomatitis, and tongue 
edema 
Endocrine Ø Ø Goiter and 
hypothyroidism  
Hematologic and 
Lymphatic 
Ø Ecchymosis and leukopenia  Anemia, eosinophilia, 
fibrin decrease, 
fibrinogen decrease, 
iron deficiency anemia, 
leukocytosis,  
lymphocytosis, 
macrocytic anemia, 
petechia and 
thrombocytopenia 
Musculoskeletal Ø Arthritis, leg cramps, 
myasthenia, twitching  
Bursitis, muscle 
atrophy, pathological  
fracture, tendinous 
contracture 
Nervous Confusion, 
paresthesia  
Akathisia,apathy,  
aphasia,CNS depression, 
depersonalization,  
dysarthria, dyskinesia, 
euphoria,hallucinations,  
hostility, hyperkinesia, 
hypertonia, libido decreased, 
memory decrease, mind racing, 
movement disorder, 
myoclonus, panic attack, 
paranoid reaction, personality 
disorder, psychosis, sleep 
disorder, stupor, suicidal 
ideation  
Choreoathetosis, 
delirium, delusions, 
dysphoria, dystonia, 
extrapyramidal 
syndrome, faintness,  
grand mal convulsions, 
hemiplegia, 
hyperalgesia,  
hyperesthesia, 
hypokinesia, hypotonia, 
manic depression 
reaction, muscle spasm, 
neuralgia, neurosis, 
paralysis, peripheral 
neuritis 
Respiratory Ø Yawn  Hiccup, 
hyperventilation  
Urogenital Ø Abnormal ejaculation, 
hematuria, impotence,  
menorrhagia, polyuria, urinary 
incontinence 
Acute kidney failure, 
anorgasmia, breast  
abscess, breast 
neoplasm, creatinine 
increase,  
cystitis,dysuria, 
epididymitis, female 
lactation, kidney 
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failure, kidney pain, 
nocturia, urinary 
retention, urinary 
urgency 
Special senses Amblyopia  Abnormality of 
accommodation,  
conjunctivitis, dry eyes, ear 
pain, photophobia, taste 
perversion,tinnitus 
Deafness, lacrimation 
disorder, oscillopsia, 
parosmia, ptosis,  
strabismus, taste loss, 
uveitis, visual field  
defect 
Metabolic and 
Nutritional Disorders 
Ø Aspartate transaminase 
increased.  
Alcohol intolerance, 
alkaline phosphatase  
increase, alanine 
transaminase increase, 
bilirubinemia, general 
edema,gamma glutamyl 
transpeptidase increase  
 
 
 Dose escalation and therapy discontinuation[46,48]: 
 The use of lamotrigine has been limited by the risk of potentially life-threatening 
dermatological reactions, principally SJS and TEN. Risk factors for these reactions include rapid 
titration, concurrent VPA administration, prior history of anticonvulsant-associated rash, female 
sex and age less than 13 years. Since the introduction of a gradual titration schedule in 1994, the 
rate of severe rashes with lamotrigine has declined from 1% to 0.1–0.01%. Although the 
incidence was reduced ten-fold after small dose introduction and slow dose escalation, the 
incidence of the severe skin reaction (SJS, TEN and hypersensitivity syndrome) induced by 
lamotrigine is still possible. Therefore in the present study, a careful dose escalation as described 
above will be applied. 
 If a decision is made to discontinue therapy with lamotrigine, a step-wise reduction of  
dose over at least 2 weeks (approximately 50% per week) is recommended unless safety  
concerns require a more rapid withdrawal. 
 
 Drug interactions: 
 The apparent clearance of lamotrigine is affected by the coadministration of certain 
medications. The net effects of drug interactions with lamotrigine are summarized in table 3. 
Table 3 : Drug Interactions with lamotrigine 
Drug Drug Plasma  
Concentration With  
Adjunctive lamotrigine 
 
Lamotrigine Plasma  
Concentration With  
Adjunctive Drugs 
Oral contraceptives (e.g.,  
ethinylestradiol/levonorgestrel) 
Bupropion  
↔ 
 
Not assessed 
↓ 
 
↔ 
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Carbamazepine (CBZ)  
CBZ epoxide 
Felbamate  
Gabapentin  
Levetiracetam  
Lithium  
Olanzapine  
Oxcarbazepine  
10-monohydroxyoxcarbazepine  
metabolite  
Phenobarbital/primidone  
Phenytoin (PHT)  
Pregabalin  
Rifampin  
Topiramate  
Valproate  
Valproate + PHT and/or CBZ  
Zonisamide 
↔ 
? 
Not assessed 
Not assessed 
↔ 
↔ 
↔ 
↔ 
↔ 
 
↔ 
↔ 
↔ 
Not assessed 
↔ 
↓ 
Not assessed 
Not assessed 
↓ 
 
↔ 
↔ 
↔ 
Not assessed 
↔ 
↔ 
 
 
↓ 
↓ 
↔ 
↓ 
↔ 
↑ 
↔ 
↔ 
 
 
 Pregnancy and lactating: 
 There are no adequate and well-controlled studies in pregnant women suggesting any 
teratogenic effects of lamotrigine. Preliminary data indicate that lamotrigine passes into human 
milk. Because the effects onthe infant exposed to lamotrigine by this route are unknown, 
breastfeeding while taking lamotrigine is not recommended. 
 
 Review of literature[48,49]: 
 Oral lamotrigine 200mg daily is a well-tolerated and moderately effective treatment for 
central post-stroke pain and central pain. Trigeminal neuralgia is a chronic pain syndrome of still 
unestablished origin. Drug therapy initially helps a great majority of patients. Lamotrigine 
appears to be the most effective. Meta-analysis suggested combination carbamazepine with 
lamotrigine or baclofen is the second-line treatment when monotherapy fails, but the evidence is 
weak. Neuropathic pain and paroxysmal symptoms are common in Multiple Sclerosis ( MS ) 
patients, although no double-blind clinical trial has been conducted to support the use of anti-
epileptic medications in MS. The principal neuropathic pain syndromes common in MS are 
trigeminal neuralgia and dysesthetic pain syndrome. Treatment is based on anti-epileptic 
medications acting on voltage-dependent sodium channels, such as carbamazepine and 
lamotrigine, or on tricyclic antidepressant. Lamotrigine is also used in preventing the cluster 
headache and in treating SUNCT( Short-lasting unilateral neuralgiform headache with conjunctival 
injection and tearing )syndrome when used in high doses for a prolonged period of time, painful 
glossopharyngeal nerve, phantom limb pain and stump hypersensitivity, post-herpetic neuralgia 
and causalgia. It was well-tolerated nad effective in HIV- associated neuropathic pain in patients  
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14 
receiving neurotoxic antiretroviral therapy and has demonstrated efficacy in relieving the pain 
associated with diabetic neuropathy. Finally , lamotrigine therapy is described in treatment of 
individuals or smaller groups of subjects such as the treatment of migraine-related vertigo, 
neuralgia after nerve section, spinal cord injury pain, postoperative analgesia and intractable 
sciatica. 
 Studies regarding lamotrigine in treatment of neuropathic pain are summarized in the 
following table: 
 
Table 4: Lamotrigine in treatment of painful neuropathy[49]. 
Study ( author, year ) Neuropathic pain Conclusion-  
Effect of lamotrigine 
Eisenberg et al, 1998 
McCleane, 1999 
McCleane, 2000 
Eisenberg et al, 2001 
Vu, 2004 
Backonja and Serra, 2004 
Singleton et al, 2005 
Vinik et al, 2007 
Coderre et al, 2007 
Chong and Hester, 2007 
Diabetic neuropathy 
Neuropathic pain 
Neuropathic pain 
Diabetic neuropathy 
Neuropathic pain 
Neuropathic pain 
Diabetic neuropathy 
Diabetic neuropathy 
Neuropathic pain 
Diabetic neuropathy 
Potentially effective 
no effect 
may be effective 
effective 
first-line or adj. Therapy 
first-line therapy 
first-line therapy 
effective 
may reduce hyperalgesia 
effective 
  
3. STUDY DESIGN 
 The present study is an open, double-blind , two – parallel groups ( drug and placebo 
)randomized phase III clinical study to portray the efficacy of lamotrigine in reducing the NRS 
score and TNS score in patients who suffer from CIPN with a duration ≥ 1 month.The study 
duration for a single patient is 24 weeks and for the study center 52 weeks. 
 Serial number 
 At the time of the study enrollment, the patients will receive a unique coded identification 
number ( serial number ) by the investigator. This coded number will be formed by the  number 
of the center in which the patient is recruited and the serial number the patient was assigned 
during the recruitment , eg 01, 02 , 03 etc. This unique serial number can not be reassigned to 
another patient once it has been assigned to a specific subject. If the patient does not finally 
participate in the study for any reason, the serial number will be recorded in the Patient 
Selection Record File along with the non-Participation reasons. 
 
 Randomization methods 
 A randomization list will be formed by or under the surveillance of the appointed 
statistician by a certified system which automatically randomly assigns patients to the two  
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treatment groups in a 1:1 ratio. The randomization program will be retested and secured after 
approval. T he patients' assignment to either of the two groups will be conducted by the 
appointed statistician and his/her team. The personnel who will be in contact with the patients 
and will perform all the study-related exams will have no access to the randomization program. 
   During the initial visit , the patients' randomization will be carried out according to 
the randomization number on the  study's drug. The randomization number will be recorded in 
the patient's Case Report Form ( CRF ) and assigns him/her in one of the two study arms. The 
randomization numbers are consecutively assigned to the patients ( no stratification is performed 
per center ). 
 The randomization process will be conducted as following:A list of all numbers (patient 1 
to patient 120 ) in ascending order will be created. Before the study initiation, a routine for 
random transpositions will be applied so that the list's elements are randomly transpositioned. 
The first half numbers will be assigned to lamotrigine and the second half will be assigned to 
placebo. All the selected patients will receive lamotrigine or placebo without the center's 
interferrence following the list's consecutive assignment. For example , the first patient will 
receive the drug respective to number 1 of the list, the second patient will receive the respective 
to number 2 of the list of drugs, etc. 
 Study drug and regimen design 
 The study drugs are lamotrigine ( trade name “ LAMICTAL ” ) tablets and placebo 
tablets. “LAMICTAL ” has a specific and unique tablet form which is described below: 
 25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25”  
 100 mg, peach, scored, shield-shaped tablets debossed with "LAMICTAL" and "100"  
 150 mg, cream, scored, shield-shaped tablets debossed with "LAMICTAL" and "150"   
 200 mg, blue, scored, shield-shaped tablets debossed with "LAMICTAL" and "200'' 
 
 The drug will be stored  at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) in a 
dry place and protected from light.In this study tablets  up to 300 mg daily , divided in two 
single doses, will be used. This means that the tablets used will be the ones of 25 mg , 100 mg 
and 150 mg. The therapy schema as described earlier in this protocol includes a 2-week period  
in the escalation phase when the patient must receive 100 mg daily. At that time, they will be 
advised to receive  two of the 25 mg tablets twice daily. The tablets will be stored at 25°C 
(77°F); excursions permitted to 15-30°C (59-86°F) in a dry place and protected from light  . 
Each tablet will  contain the labeled amount of lamotrigine and the following inactive 
ingredients: lactose; magnesium stearate; microcrystalline cellulose; povidone; sodium starch 
glycolate; FD&C Yellow No. 6 Lake (100 mg tablet only); ferric oxide, yellow (150 mg tablet 
only); and FD&C Blue No. 2 Lake (200 mg tablet only).  
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 Blindness control  
 This study is a double-blind study. Because of the very unique form of the tablet , which 
is described above in the  “ Study drug ” section in order to preserve the investigator's blindness 
, an identical placebo tablet has been manufactured by the pharmaceutical company and will be 
preserved separately at the sponsor's site and finally the drug administered is unknown to the 
investigator and their designated personnel. 
 
 Summary of the study procedures 
 Patients meeting the inclusion criteria, which will be checked during a screening period, 
will participate in the study after signing the informed consent form ( initial visit, visit 1 ). At 
this initiation visit , the subjects will be asked to complete the QLQ-CIPN20 questionnaire as 
well as estimate their pain severity using the NRS score. A baseline TNS score will also be 
obtained by the expert neurologist of the study, as well as a thorough physical examination , 
ECG and blood test analysis. In this visit the patients will be randomized in the two arms ( 
lamotrigine and placebo ) and will be given extended advice on the drug use. They will be 
strongly advised to take the tablet at the same time once daily  ( at bed time ) for 2 weeks , then 
twice daily at a standard time with a 12 hour space between the two doses ( e.g. at 9:00 and at 
21:00 ) and also be reminded that there will be a 2-week period when they must take two tablets 
at every scheduled time of the day. They will also be asked to fill the quality of life 
questionnaire at the end of every single week of therapy. In order to make sure they have done 
so , the investigator or his/her staff will make a phone call at the end of every week to check on 
the patients and remind them of the questionnaire. During this phone call they will be asked by 
the investigator to rate their pain severity and so a NRS score will be obtained. 
 At the end of every 2-week period , if no adverse reactions or events have taken place in 
the mean time, the patients will visit the study center, where they will be physically examined 
and undergo ECG , blood tested, submit the filled questionnaires and also the new NRS and 
TNS scores will be obtained. 
 In conclusion the number of scheduled visits is 10: 
 Visit 1 : Initial visit 
 Visit 2 : End of 2nd week of therapy ( initial dose 25 mg at bed time) 
 Visit 3 : End of 4th week of therapy ( escalated dose 25 mg twice daily ) 
 Visit 4 : End of 6th week of therapy ( escalated dose 50 mg twice daily ) 
 Visit 5 : End of 8th week of therapy ( escalated dose 100 mg twice daily ) 
 Visit 6 : End of 10th week of therapy ( escalated dose 150 mg twice daily ) 
 Visit 7 : End of 14th week of therapy ( maximum dose ) 
 Visit 8 : End of 18th week of therapy 
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 Visit 9 : End of 20th week of therapy ( end of the 12-week period of maximum dose       
- start of drug- tapering off and exact advise of the tapering off  process .) 
 Visit 10 : End of 24th week ( End of the tapering off period ) 
 In case any patient reaches their maximum tolerated dose earlier ( e.g. 200 mg daily ), 
they will start the 12-week period of steady dose earlier (at the respective time ) and pay less 
visits to the investigation center.  
 
4. SELECTION AND ENROLLMENT OF SUBJECTS 
 
4.1 Inclusion criteria 
 DISEASE CHARACTERISTICS: 
 Diagnosis of cancer  
 Received, or are currently receiving, neurotoxic chemotherapy, including any of the 
following: 
 Taxanes (e.g., paclitaxel or docetaxel)  
 Platinum-based compounds (e.g., carboplatin, cisplatin, or oxaliplatin)  
 Vinca alkaloids (e.g., vincristine or vinblastine)  
 Proteasome inhibitors ( e.g. bortezomid ) 
 Experiencing pain or symptoms of peripheral neuropathy for at least 1 month attributed to 
chemotherapy 
 Average daily pain rating of at least 4 out of 10 NRS  
 Peripheral neuropathy at least grade 1  using  TNS neuropathy rating  
  
 PATIENT CHARACTERISTICS: 
  Age 
 18 and over  
  Life expectancy 
 At least 6 months  
  Hepatic 
 Bilirubin < 2 times upper limit of normal (ULN)  
  Renal 
 Creatinine ≤ 1.5 times ULN  
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 Other 
 Fertile patients must use effective contraception  
 Able to complete questionnaires  
  
 PRIOR CONCURRENT THERAPY: 
  
 Chemotherapy 
 See Disease Characteristics  
 More than 7 days since prior methotrexate or other dihydrofolate inhibitors  
           
  Other 
 More than 7 days since prior, and no concurrent use of any of the following: 
 Tricyclic antidepressants (e.g., amitriptyline, nortriptyline, or desipramine) 
 Concurrent selective serotonin reuptake inhibitors allowed  
 Monoamine oxidase inhibitors  
 Opioid analgesics  
 Anticonvulsants (e.g., gabapentin, topiramate, valproic acid, or clonazepam)  
 Adjuvant analgesics (e.g., mexiletine) 
 Prior nonsteroidal anti-inflammatory drugs allowed  
 Topical analgesics (e.g., lidocaine gel or patch) to the affected area  
 Amifostine  
 More than 30 days since prior investigational agents for pain control  
 No other concurrent investigational agents for pain control 
4.2 Exclusion Criteria 
      Pregnant or nursing  
  Positive pregnancy test  
       Prior allergic reaction or intolerance to lamotrigine  
  Extreme difficulty swallowing pills  
  Other identified causes of painful paresthesia preceding chemotherapy, including 
 any of the following: 
◦ Radiation or malignant plexopathy  
◦ Lumbar or cervical radiculopathy  
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 Pre-existing peripheral neuropathy of another etiology, such as any of the following: 
▪ Cyanocobalamin deficiency  
▪ AIDS  
▪ Diabetes  
▪ Heavy metal poisoning amyloidosis  
▪ Syphilis  
▪ Hyperthyroidism or hypothyroidism  
▪ Inherited neuropathy  
▪ Significant psychiatric illness (e.g., mania, psychosis, or schizophrenia) that 
would preclude study participation  
 
 
 4.3 Withdrawal criteria 
 
 Since participation in the clinical trial is completely voluntary the patients can  
withdraw from the study at any given time they wish to do so,without having any personal or 
medical cost, as it is clearly described in the informed consent form. 
 In the same way , the investigator can remove any patient from the study under various 
circumstances ( e.g. violation of inclusion criteria, patient safety, etc ) and the exact reasons of 
patient withdrawal must be extensively reported in the patient report form and also analyzed in 
the final report. 
 The primary objective's  statistical analysis is based on the per protocol 
population,therefore the participating must be carefully chosen , so that the withdrawal 
percentage does not exceed 10 %. 
 
 
 
 
4.4   Study enrollment procedures 
 
  For the patient selection, medical history will be thoroughly examined by the 
investigator. During the patient selection phase, patients with specific co-existing diseases will 
be detected after thorough study of the medical history and personal data, physical examination 
and laboratory testing and will be excluded from the study. 
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5. STUDY INTERVENTIONS 
 
 
 5.1 Interventions , Administration and Duration 
 The study drug is Lamotrigine given orally in tablets of 25 , 100 and 150 mg , which is 
compared to identical placebo, given by the same route and at the same dosage. Patients will be 
started on a placebo or lamotrigine at dose of 25 mg at bed time for 2 weeks, then 25 mg twice 
daily for 2 weeks, then 50 mg twice daily for 2 weeks , then 100 mg twice daily for 2 weeks and 
then the dose will be escalated to 150 mg twice daily, at which time therapy will continue for 12 
weeks. Dose escalation will be continued per this schedule to allow each patient to reach his/her 
tolerated dose. After a total of 20 weeks of therapy from the time of drug initiation patients will 
be tapered off this drug / placebo  over a 4-week period. If a patient wishes to stop sooner for 
any reason before 20 weeks , he/she will be encouraged to taper the drug over a 4-week period 
rather than discontinuing therapy abruptly. 
 
 
 5.2 Handling of study interventions 
 The sponsor of the clinical study will be responsible for the supply of both the drug and 
the placebo. The products will be sent to each center by the sponsor/manufacturer, packed 
according to the randomization program and labeled according to the current law and the GMP 
compliance. Caution will be taken for the right storage of the drugs. In a room with a room 
temperature of 20-30 º C and a humidity of 50-60 % , while temperature and humidity will be 
monitored daily. The investigational products will be available only for the current study under 
the responsibility of the prime investigator, who has to ensure that they will not be used outside 
the current study and in any undesirable ways. The investigator will be checked and has to 
certify the use of each drug and keep detailed records in the Case Report Form. A detailed file of  
distribution has to be written and updated by the investigator. Full and empty bottles of the 
administered drug will be returned to the monitor of the CRO at the end of the study. 
 
 
 
 5.3 Concomitant interventions 
 Any concomitant therapy before or during the clinical study will be recorded in the Case 
Report Form. The investigator , by checking the inclusion criteria will decide whether the 
patient can enter or go on with the study. The concomitant therapy has to be standard and not 
changed during the study. There are several drugs that cannot be concurrently administered and 
if a need comes up for any of them to be administered to the patient, then he'she will have to 
report it immediately to the investigator and leave the study. 
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 5.4 Adherence Assessment 
 Since the patients will receive the medication at home , they will be asked to bring the 
bottle with the remaining tablets at every visit ( every 2 weeks ) , when the number of the 
remaining tablets will be counted and recorded at the Case Report Form. At the end of the 
therapy the patients will be asked to return the bottle to the investigator. In addition at the 
weekly  scheduled phone call the patients will be reminded of the therapy regimen ( colour of 
pill, daily dosis ). 
 
 
 
6. CLINICAL AND LABORATORY EVALUATIONS 
 
 
6.1 Schedule of evaluations 
 
 Visit 1 :   Baseline NRS, TNS , QLQ-CIPN20, ECG Blood test analysis for: 
       Hb, Ht, Cr , TBIL, Glucose ,B12 ,Vitamin K,cGTP(female patients) ,       
       TSH,FT3, FT4, HbA1C, HIV test and PCR for the detection of   
            Treponema Pallidum, physical examination 
 Visit 2-9 :  NRS, TNS , QLQ-CIPN20, ECG, Blood test analysis for: 
          Hb, Ht, Cr , TBIL, Glucose , B12 ,Vitamin K, cGTP ( female      
                 patients ), TSH, FT3, FT4, HbA1C, physical examination 
       Visit 10 :  NRS , TNS , QLQ-CIPN20, ECG, Hb, Ht, Cr , TBIL, Glucose , B12 ,                             
          Vitamin K,cGTP ( female patients ), TSH, FT3, FT4, HbA1C,                               
          physical examination. 
 
 
 
  
 6.2 Timing of evaluations 
 The TNS score will be obtained at the patients' visits to the investigation center, while 
NRS will be evaluated weekly by telephone and QLQ-CIPN20 will be answered weekly by the 
patients and handed to the investigator at the  patients' visits, when they will also submit in 
writing the NRS score, so it can be compaired with the values given per phone. In case of great 
differences in the values, the patients will be asked to try to remember whether the pain was 
intense or not and if they are not able to recall that either a mean value will be noted as the 
correct one. 
 
     6.3 Special Instructions and Definitions of Evaluations 
 In the present clinical study three different evaluation tests will be used: 
 
 
 
 
22 
 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:29 EEST - 137.108.70.6
Efficacy of lamotrigine in the management of CIPN 
Version 1 
09 August 2015 
 
 
 
1. Numerical Rating Scale (NRS) for the evaluation of pain intensity.  
   
  The patient is asked to make three pain ratings, corresponding to current, best  
 and worst pain experienced over the past 24 hours.  
  The average of the 3 ratings will be used to represent the patient’s level of pain  
 over the previous 24 hours. 
  Patient Instructions (adopted from (McCaffery, Beebe et al. 1989): 
  “Please indicate the intensity of current, best, and worst pain levels over  
  the past 24 hours on a scale of 0 (no pain) to 10 (worst pain imaginable)” 
 
2. Total Neuropathy Score (TNS) for the quantitative assessment of peripheral neuropathic 
symptoms and signs 
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  3. Quality of Life Questionnaire - CIPN20  
 
  The QLQ-CIPN20 contains 20 items assessing sensory (9 items), motor (8 items), 
and autonomic symptoms (3 items). Using a 4-point Likert scale (1 = “not at all,” 2 = “a little,” 
3 = “quite a bit,” and 4 = “very much”), individuals indicate the degree to which they have 
experienced sensory, motor, and autonomic symptoms during the past week. Sensory raw scale 
scores range from 1 to 36, motor raw scale scores range from 1 to 32, and autonomic raw scale 
scores range from 1 to 12 for men and 1–8 for women (erectile function item is excluded). All 
scale scores are linearly converted to a 0–100 scale, with higher scores indicating more 
symptom burden.  
 
 QLQ CIPN20 items: 
 
1. Did you have tingling fingers or hands?a 
2. Did you have tingling toes or feet?a 
3. Did you have numbness in your fingers or hands?a 
4. Did you have numbness in your toes or feet?a 
5. Did you have shooting or burning pain in your fingers or hands?a 
6. Did you have shooting or burning pain in your toes or feet?a 
7. Did you have cramps in your hands?b 
8. Did you have cramps in your feet?b 
9. Did you have problems standing or walking because of difficulty feeling the ground 
under your feet?a 
10. Did you have difficulty distinguishing between hot and cold  water?a       
11. Did you have a problem holding a pen, which made writing difficult?b 
12. Did you have difficulty manipulating small objects with your fingers (for example, 
fastening small buttons)?b 
13. Did you have difficulty opening a jar or bottle because of weakness in your hands?b 
14. Did you have difficulty walking because your feet dropped downwards?b 
15. Did you have difficulty climbing stairs or getting up out of a chair because of weakness 
in your legs?b 
16. Were you dizzy when standing up from a sitting or lying position?c 
17. Did you have blurred vision?c 
18. Did you have difficulty hearing?a 
 
Please answer the following question only if you drive a car 
      19. Did you have difficulty using the pedals? 
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      20.             Did you have difficulty getting or maintaining an erection?c 
 
aSensory scale items 
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bMotor scale items 
cAutonomic scale items 
 
 
 
 
7. MANAGEMENT OF ADVERSE EXPERIENCES 
 
 The definition adverse experiences consists of two separate terms. Adverse Events and 
Adverse Reactions.  
 An adverse event ( AE ) can be any unintended , unpleasant reaction ( including abnormal 
laboratory findings ), symptom, diagnosis, major clinical deviations from baseline, vital signs , 
clinical deterioration of any concurrent diseases recorded at the time of study initiation or any 
new clinical manifestation coincidental with the initiation of the investigational product. 
Pathological clinical signs observed or measured during the study will be defined as Adverse 
Events, only if: 
 
 It causes clinical signs or symptoms or 
 needs therapy or 
 urges the interruption of therapy  
 
 Adverse events related to the underlying disease will not be considered as serious but will 
recorded at the CRF. In any case the causality should be defined and the  sponsor  must be 
informed. 
 Adverse events reported by the patient or the investigator will be recorded  individually at 
the CRF : the specific event, whether it occurred prior to the study  initiation or not, the exact 
date it happened, the severity, the duration ,the intensity, its  relevance to the study drug, 
specific measures taken and its outcome. Patients  showing adverse events at the time of the 
final visit will be followed up for 30 days  and the events will be documented. Serious 
adverse events will be followed up until  they are resolved. All this information will be reported 
to the sponsor. 
 Adverse events are considered serious ( SAE ) if ( regardless the dose of the drug) : 
 It leads to death 
 It is life threatening 
 It causes permanent or significant disability  / incompetence 
 it causes congenital abnormality  
 it leads to hospital admittance or prolongation of hospital stay 
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An Adverse Reaction ( ADR ) is any unpleasant and unexpected reaction to the investigational 
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product related to the administered dose , whose intensity does not comply with the 
investigator's brochure or the insert package information. 
 The drug's relevance to the ADR must be defined by a medically authorized person  
as follows: 
 Relevant: The ADR follows the drug administration and cannot be logically    
   attributed to any other cause. 
 Irrelevant: The ADR possibly derives from the patient's condition or other  concurrent  
   therapy. 
   
 The ADRs are classified regarding their severity as: 
  
 Mild: Does not affect daily activities 
 Moderate: Affects the usual daily activities 
 Serious: Inability to perform daily activities 
 
 All adverse experiences will be documented by the investigator in the CRF whether or 
not they are attributed to the drug. A description of the adverse experience , date of start and 
recession, severity, clinical relevance to the drug and  applied measures must be reported. A 
follow up must be upheld, if necessary. ADRs  must be followed up until recession or 
stabilization. If they lead to patient withdrawal  there must be followed up until a satisfactory 
solution is given. Whether or not the patient decides to withdraw from the study due to an 
adverse reaction , he/she should be provided with the proper medical care until their 
improvement or stabilization.  
 In case of SAE , the investigator must immediately communicate with the  sponsor either 
by phone or per fax within 24 hours of the event. The sponsor will  check the report and ask of 
any additional information. The sponsor will immediately submit security reports to the 
regulatory authorities and will inform the investigators about the regulatory reports. The 
investigators must file security reports  according to the Investigation Review Board ( IRB ) / 
National Ethics Committee within specific time defined by the local regulatory authorities. The 
documentation of the immediate security report admission and reception must be preserved in 
the investigation center.  
 Any case of pregnancy during the study or within 30 days after completion of therapy 
should be reported to the sponsor as a SAE. The expected time of birth, pregnancy termination, 
information about the neonate, etc must be included. The investigator is obliged to documenting 
both the mother's and fetus' medical condition. 
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8. CRITERIA FOR INTERVENTION DISCONTINUATION 
 
       The sponsor can at any time disrupt the study if he/she has information about      
 issues concerning quality, effectiveness, safety of the drugs being studied, or any other 
information that could affect the correct conduction of the study. The sponsor has the right to 
send a written termination announcement, quoting the reasons of the termination. 
      If the investigator intents to withdraw his participation in the study he/she is obliged to 
inform the sponsor and refer to the reasons leading to his withdrawal. 
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9. STATISTICAL CONSIDERATIONS 
 
           9.1 General design issues 
 The statistical analysis will be coordinated by the assigned bio-statistician. A statistical 
analysis plan will be written which will include every single detail. Before securing the database, 
every questionable case , that has difficulties in being assessed clearly will be thoroughly 
examined by the database operator, the assigned bio-statistician and the study administrator. 
 The study will employ a randomized , double-blind, parallel group ( drug vs placebo ) 
design to determine the efficacy of lamotrigine in treatment of CIPN. The NRS score will be 
used to measure the primary outcome, which is the efficacy of lamotrigine on CIPN-related pain 
relief. The TNS score which is considered according to literature valid and reliable and a highly 
valid and reliable questionnaire , specific for assessment CIPN patients' quality of life will be 
used to measure the secondary outcomes.  
 No p-value correction has to be applied , since there is only one primary end point.  
 The subjects will be stratified by gender , chemotherapy agent receiving/-ed and by 
whether they are currently receiving chemotherapy or they have completed their cancer 
treatment. 
 The subjects  that undergo no ADRs will be followed for 3 months after study 
completion. 
 
 
9.2 Outcome  
  In the present study , one primary and two secondary outcomes will be  measured. The 
primary outcome is the mean difference between the baseline NRS  score and the NRS score at 
the end of the study. The secondary outcomes are the  mean difference between the baseline and 
the final TNS score as well as the mean difference between the QLQ-CIPN20 scores in the 
beginning and at the end of the study. 
 
9.3 Sample size and accrual 
 In order to estimate the sample size for the study, the power approach for two-
independent groups will be used. 
In calculating the sample size for the clinical trial , the following parameters are defined: 
 The difference ( μ1) in average mean NRS score in the placebo arm, according to 
 literature is 0.5 and the SD= 0.57. 
A decrease in average mean NRS score to 0.3 ( μ2 ) in the lamotrigine arm is considered as 
clinical significant, so Δ= μ1 – μ2 = 0.2 .   
The p-value is set at 0.05 and the power at 80%. After the adjustment of an extra 10% 
that could withdraw from the study the sample size is estimated to be 120 patients ( 60 
subjects in each arm ) .  
 The patient randomization will be stratified. There is no sample size goal for each 
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stratum. The patients will be assigned to strata according to the strata characteristics. 
 
   
9.4 Data monitoring 
 
  The study duration is 52 weeks. Interim monitoring visits are scheduled once a 
month after the first patient's study initiation. There will be one interim analysis once half of the 
patients participating in the study complete their 12 - week period of treatment with their 
maximum tolerated dose. 
  In case, after the 28-week period given to patient recruitment, during the monitor's 
visit one or more of the following is noted , the study will be discontinued: 
 
 Slow Accrual ( less than 2 patients recruited weekly ) 
 High Losses to follow-up ( more than 30% missing data ) 
 Poor quality control ( inappropriate or unmonitored study drug storage 
conditions,poor service of the  medical equipment used in the study, e.g. 
electromyographs, poor storage conditions for the blood samples, 
inadequate follow up by telephone due to failure or omission, misfilled or 
misfiled questionnaires > 30% ) 
 More than 2 reports of SAEs  
 Inadequate update of CRFs  
 Major protocol violations 
  No separate monitoring considerations for each stratum are demanded.  
 
9.5 Data analysis 
 The primary analysis will be conducted according to per protocol analysis. In addition , in 
order to compensate for the missing data an ITT ( intention-to-treat) analysis will be also 
conducted. 
 The primary objective is the mean difference in NRS score between baseline and final 
visit. A co-variation analysis ( ANCOVA ) having the treatment set as a factor and the baseline 
NRS score as a co-variate. The difference between means and the 95% CI will be calculated. 
The null hypothesis is that lamotrigine and placebo are equal in reducing the mean NRS score. 
The secondary objectives will be also measured using ANCOVA, where TNS  and QLQ-CIPN20 
baseline scores will be respectively set as co-variates. 
 The analysis of the above data will be done per stratum. There will be three strata in our 
analysis: gender , chemotherapy agent and whether chemotherapy is active or has ended either 
due to completion or to discontinuation. 
The demographic patient data at study initiation ,as well as the baseline Creatinine and TBIL 
values, will be compared using the parametric independent t-test or the non-parametric Mann-
Whitney U- test for numerical values and the chi-square test or Fisher's exact test for categorical 
values. 
 An adverse reaction occurrence comparison will be conducted applying a chi-square  test. 
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 10. DATA COLLECTION AND SITE MONITORING  
 
 10.1 Records to be kept 
      Documents related to the clinical study must be kept with the investigator's        
resposibility until the completion of the study.   
           With the completion of the clinical study records will be classified and stored in         
the general archive according to the standards of correct clinical practice. 
 
 10.2 Role of Data Management 
                   Relevant information will be documented with either a blue or a black pen on the 
CRF. The CRFs must be filled out in a legible way in order to facilitate the statistical analysis. 
By the end of the study every information on the CRF will be evaluated for the elaboration of 
the final report. 
  If corrections have to be made, false information must be erased with a single line 
so that they remain legible and corrected data must be documented,  signed and dated. The CRF 
must contain the instructions mentioned above. 
 
 10.3 Quality Assurance 
 
                    The progress of the clinical trial will be under constant supervision.Supervisors will 
be appointed by the sponsor. Frequent communication must be agreed  between supervisors and 
investigators. 
          The supervisor will be responsible for the compliance to the protocol and the integrity, 
coherence and reliability of the data and must therefore have access to the patients medical 
history and files. The investigator must accept to cooperate 
with the supervisor in order to detect and solve any problems. 
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      11. HUMAN SUBJECTS 
 
      11.1 Ethics and Informed Consent 
 
                The clinical trial must be conducted according to the international norms,  
local legal commitments, the declaration of Helsinki and the instructions for correct  
clinical practice ( ICH GCP ). 
       A copy of the above mentioned files will be given to the investigators. 
      The instructions for correct clinical practice are an international ethical and  
scientific quality pattern about the design, conduction, documentation and report of clinical 
studies involving human subjects. 
      The conformity to this pattern is a declaration in public that rights, safety and 
prosperity of the individuals participating in clinical trials is protected according the declaration 
of Helsinki, and that medical data are credible. 
     The investigator agrees by signing to conform to the instructions and methods of  this 
particular protocol,the directives of the declaration of Helsinki, and local legal commitments. 
The investigator as well as his/her team are obliged to submit to these rules. 
    The clinical trial will start only after the consent of the national ethics committee about 
drugs is acquired. 
   With the exception of emergencies, changes or deviations from the protocol 
are not allowed without the approval of the ethics committee and/or the drug organization. The 
committee is to be informed about any changes and must approve 
any deviation that could raise the patients' risk and /or could effect negative the  
patients' rights or the reliability of the study. This is not possible for changes made 
to reduce patients' suffering and danger, or changes concerning administrative 
matters. 
  Every patient is to be informed about the characteristics of the clinical trial 
by verbal and written means ( through an information flyer ) and the ICF that will contain 
information about: 
    
 the rights of the individuals participating in the clinical trial 
 
 the goal of the study 
 
 issues concerning the methods used 
 
 therapies that are to be studied 
 
 potential risks and dangers 
 
 possible unwanted reactions 
 
 access to confidential files 
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 investigators 
 
 
    After the patient is fully informed about all aspects and restrictions 
of the protocol of the clinical trial he/she must sign the informed consent 
document with the investigator before being enrolled in the study. With this signature  
the individual declares that he/she participates voluntarily and his intention to  
fulfill the protocol of the clinical trial and the investigator's instructions.  
  The patient must keep this signed Informed Consent document and information sheet 
during the clinical trial as well as the investigator's contact data. 
The investigator must also keep the signed Informed Consent in his/her files. 
 
11.2 Subject Confidentiality 
 The investigators must guarantee the anonymity of the individuals participating in the 
clinical trial. Neither in the CRF nor in any other file is it allowed for the patients to be 
recognizable by their names but only by an identity code. The investigator has to keep the file 
with the matching of codes and names. These files will not be handed over to the sponsor and 
are to kept under strict confidentiality by the main investigator. 
  Confidential data must be accessible only to the staff participating in the clinical trial, to 
the supervisors appointed by the sponsor and the competent authorities, as well as the ethics 
committee responsible for the particular study. 
 Access to the data will also be permitted to the statistic analyst who will be responsible 
for preserving the anonymity of the individuals. 
 Medical files as well as every study-related document are to be kept by the investigator 
and must be locked up for the agreed period of time.  
 
11.3 Study Modification 
 
  In case of new information necessary for the correct conductance of the clinical trial that 
should lead to any deviation of the protocol the sponsor is to inform the responsible authorities 
as well as every investigator participating in the study. 
The head of the investigation is responsible to inform the IRB/IEC and if necessary  
modifying the information for  participants. 
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12. PUBLICATION OF RESEARCH FINDINGS 
 
  The results of the clinical trial will be discussed and reviewed by the investigators and 
the sponsors for the upcoming publication. 
  The results are not to be discussed with any other person until an agreement is signed by 
the sponsor concerning a lecture or the publication of an article. 
  As an exception, the investigators will be allowed to include the title of the clinical trial 
in their curriculum vitae.  
 
    13. LIST OF ABBREVIATIONS AND MEDICAL TERMS 
 
           
        
ADR Adverse Drug Reaction 
AE Adverse Experience 
AED Anti-Epileptic Drug 
CBZ CarBamaZepin 
CGTP Chorionic GonadoTroPin 
CIPN Chemothrapy Induced Peripheral Neuropathy 
CNS Central Nervous System 
Cr Creatinine 
CRF Case Report Form 
DRG Dorsal Root Ganglia 
Hb Hemoglobin 
HIV Human Immunodeficiency Virus 
Ht Hematocrit 
IC Informed Consent 
ICH-GCP International Conference of Harmonization – Good Clinical Practice 
IRB Institutional Review Board 
ITT Intention To Treat 
MS Multiple Sclerosis 
NCI-CTC National Cancer Institute – Common Toxixity Criteria 
NMDA N-Methyl-D-Aspartate 
NRS Numerical Rating Scale 
NSAIDs Non Steroid Anti-Inflammatory Drugs 
PHT Phenytoin 
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QLQ Quality of Life Questionnaire 
SAE Serious Adverse Event 
SJS Steven-Johnson Syndrom 
SUNCT Short-lasting Unilateral Neuralgiform headache with Conjunctional injection and 
Tearing 
TBIL Total BILirubin 
TEN Toxic Epidermal Necrolysis 
TNS Total Neuropathy Score 
TRPV Transient Receptor Potential Vanilloid 
TSH Thyroid Stimulating Hormone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34                       
14. REFERENCES 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:29 EEST - 137.108.70.6
Efficacy of lamotrigine in the management of CIPN 
Version 1 
09 August 2015 
 
     
[1] Basic Science and clinical management of painful and non-painful chemotherapy-related 
neuropathy, J.H. Kimet et al. , Gynecologic Oncology 136, (2015) 453-459. 
[2] Chemotherapy-induced neuropathy, Bharga A et al., Curr. Oncol. Rep. 2007;9;290-9. 
[3] Bokhari F, Sawatzky JA. Chronic neuropathic pain in women after breast cancer 
 treatment. Pain Manag Nurs 2009;10:197–205. 
 [4] Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A 
 systematic review and meta-analysis, Marta Seretny et al., PAIN 155 (2014) 2461–2470. 
 [5] Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by 
 cisplatin and related compounds. Cochrane Database Syst Rev 2011;2(CD005228). 
 [6] Polomano RC, Farrar JT. Pain and neuropathy in cancer survivors. Cancer Nurs 2006; 
 29(Suppl. 2):39–47. 
[7] Reyes-Gibby C,Morrow PK, Bennett MI, et al. Neuropathic pain in breast cancer survivors: 
using the ID pain as a screening tool. J Pain Symptom Manage 2010;39: 
 882–9. 
[8] Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of 
life among patients with chemotherapy-induced painful peripheral 
 neuropathy: a randomized clinical trial. JAMA 2013;309:1359–67. 
[9] Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of 
doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced 
 endometrial cancer: results from GOG 184. Gynecol Oncol 2010;119:538–42. 
[10] Massey RL, Kim HK, Abdi S. Brief review: chemotherapy-induced painful peripheral 
neuropathy (CIPPN): current status and future directions. Can J Anaesth 2014 Aug; 
 61(8):754–62. 
[11] Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between 
dosage, time, and platinum concentration in neurologic tissues, and 
 morphologic evidence of toxicity. J Clin Oncol 1992;10:795–803. 
[12] Zhang H, Boyette-Davis JA, Kosturakis AK, et al. Induction ofMCP-1/CCR2 in primary 
sensory neurons contributes to paclitaxel-induced neuropathy. J Pain 2013;14(10): 1031–44. 
[13] Li Y, Zhang H, Zhang H, et al. Toll-like receptor 4 signaling in primary sensory neurons and 
spinal astrocytes contribute to paclitaxel-induced peripheral neuropathy. 
 J Pain 2014;15(7):712–25 
[14] Zhang H, Dougherty PM. Enhanced excitability of primary sensory neurons and altered 
gene expression of neuronal ion channels in dorsal root ganglion in 
 paclitaxel-induced peripheral neuropathy. Anesthesiology 2014;120(6):1463–75. 
[15] Massey RL, Kim HK, Abdi S. Brief review: chemotherapy-induced painful peripheral 
neuropathy (CIPPN): current status and future directions. Can J Anaesth 2014 Aug; 
61(8):758–62. 
[16] Sun X, Windebank AJ. Calcium in suramin-induced rat sensory neuron toxicityin vitro. 
Brain Res 1996;742:149–56. 
[17] Siau C, Bennett GJ. Dysregulation of cellular calcium homeostasis in 
chemotherapyevokedpainful peripheral neuropathy. Anesth Analg 2006;102:1485–90. 
 
 
 
 
35 
[18] Xiao W, Boroujerdi A, Bennett GJ, et al. Chemotherapy-evoked painful peripheral 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:29 EEST - 137.108.70.6
Efficacy of lamotrigine in the management of CIPN 
Version 1 
09 August 2015 
 
neuropathy: analgesic effects of gabapentin and effects on expression of the 
 alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007;144:714–20. 
[19] Matsumoto G, Ichikawa M, Tasaki A, et al. Axonal microtubules necessary for generation of 
sodium current in squid giant axons: I. Pharmacological study on sodium current and restoration 
of sodium current by microtubule proteins and 260 K protein.J Membr Biol 1984;77:77–91. 
[20] Nieto FR, Entrena JM, Cendan CM, et al. Tetrodotoxin inhibits the development and 
expression of neuropathic pain induced by paclitaxel inmice. Pain 2008;137:520–31. 
[21] Ghelardini C, Desaphy JF, Muraglia M, et al. Effects of a new potent analog of tocainide on 
hNav1.7 sodium channels and in vivo neuropathic pain models. 
 Neuroscience 2010;169:863–73. 
[22] Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due 
to remodelling of ion channel expression in nociceptors. EMBO Mol Med 2011; 3:266–78. 
[23] Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful 
peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 
 122:245–57. 
[24] Melli G, TaianaM, Camozzi F, et al. Alpha-lipoic acid preventsmitochondrial damage and 
neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008; 
 214:276–84. 
[25] Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated 
with bortezomib and vincristine in patients with newly diagnosed multiple myeloma:a 
prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 
2010;11:1057–65. 
[26]Joseph EK, Chen X, Bogen O, et al. Oxaliplatin acts on IB4-positive nociceptors to induce 
an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 
 2008;9:463–72. 
 [27] Kim HK, Zhang YP, Gwak YS, et al. Phenyl N-tert-butylnitrone, a free radical scavenger, 
 reduces mechanical allodynia in chemotherapy-induced neuropathic pain in 
 rats. Anesthesiology 2010;112:432–9. 
 [28] Muthuraman A, Jaggi AS, Singh N, et al. Ameliorative effects of amiloride and pralidoxime 
 in chronic constriction injury and vincristine induced painful neuropathy 
 in rats. Eur J Pharmacol 2008;587:104–11. 
 [29] Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in therat. 
 Eur J Neurosci 2004;20:2896–902 
 [30] Boehmerle W, Zhang K, Sivula M, et al. Chronic exposure to paclitaxel 
 diminishesphosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 
 degradation. Proc Natl Acad Sci U S A 2007;104:11103–8. 
 [31] Alessandri-Haber N, Dina OA, Joseph EK, et al. Interaction of transient receptor potential 
 vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. JNeurosci 
 2008;28:1046–57. 
 [32] Ta LE, Bieber AJ, Carlton SM, et al. Transient receptor potential vanilloid 1 is essential for 
 cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010;6:15. 
 [33] Anand U, Otto WR, Anand P. Sensitization of capsaicin and icilin responses in oxaliplatin 
 treated adult rat DRG neurons. Mol Pain 2010;6:82. 
 [34] Horvath P, Szilvassy J, Nemeth J, et al. Decreased sensory neuropeptide release in isolated 
 bronchi of rats with cisplatin-induced neuropathy. Eur J Pharmacol 2005;507:247–52. 
  
 
36 
 [35] Jamieson SM, Liu JJ, Connor B, et al. Nucleolar enlargement, nuclear eccentricity and 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:29 EEST - 137.108.70.6
Efficacy of lamotrigine in the management of CIPN 
Version 1 
09 August 2015 
 
 altered cell body immunostaining characteristics of large-sized sensory neurons  following 
 treatment of  rats with paclitaxel. Neurotoxicology 2007;28:1092–8. 
 [36] Thibault K, Van Steenwinckel J, Brisorgueil MJ, et al. Serotonin 5-HT2A receptor 
 involvement and Fos expression at the spinal level in vincristine-induced neuropathy 
 in the rat. Pain 2008;140:305–22. 
 [37] Hansen N, Uceyler N, Palm F, et al. Serotonin transporter deficiency protects mice from 
 mechanical allodynia and heat hyperalgesia in vincristine neuropathy.Neurosci Lett 
 2011;495:93–7. 
 [38] Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters 
 voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000;406:25–32. 
 [39] Grolleau F, Gamelin L, Boisdron-CelleM, et al. A possible explanation for a neurotoxic 
 effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.  
 J Neurophysiol 2001;85:2293–7. 
 [40] Park SB, Krishnan AV, Lin CS, et al. Mechanisms underlying chemotherapy-induced 
 neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 
 2008;15:3081–94. 
 [41] Meijer C, de Vries EG,Marmiroli P, et al. Cisplatin-induced DNA-platination in 
 experimental DRG neuronopathy. Neurotoxicology 1999;20:883–7 
 [42] Argyriou AA, Koltzenburg M, Polychronopoulos P, et al. Peripheral nerve damage 
 associated with administration of taxanes in patients with cancer. Crit Rev Oncol 
 Hematol 2008;66:218–28. 
 [43] Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in 
 the rat induces a peripheral sensory neuropathy characterized by macrophage 
 infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007;203:42–54. 
 [44] Early predictors of peripheral neurotoxocity in cisplatin and paclitaxel combination 
 chemotherapy, Cavaletti et al., Annals of Onc. 15;1439-1442,2004. 
 [45] CIPN: A critical analysis, Park et al. , CA CANCER;2013;63;419-437 
 [46] Lamictal package insert  
 [47] Efficacy of lamotrigine in the management of CIPN, Rao et al.,Cancer June 2008;2802-
 2808.  
 [48] Clinical research amd monitoring in lamotrigine patients: A  pharmacoepidemiologic Study 
 in the UK , Wong et al, Epilepsia, 4212; 237-244, 2001.  
 [49] Lamotrigine in the treatment of pain syndromes and neuropathic pain , Titlic M. et al., 
 Bratiz/Lek Listy 2008;109, 421-424. 
 
 
 
 
 
 
 
 
 
37 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:29 EEST - 137.108.70.6
